Congressional committees have advanced initial measures to address prescription drug costs. However, their work to date has not focused on the significant policy changes needed to meaningfully lower drug prices. To address the drivers of excessive prescription drug prices in the United States, the Coalition for Fair Drug Prices urges Congress to enact meaningful policies that leverage the federal government’s power to negotiate drug prices.
This guide outlines model policies for states to consider to rein in drug prices in 2019 and beyond. Those discussed first most directly target drug prices and therefore are likely to have the greatest impact. This piece also cautions against prioritizing approaches to import drugs from Canada, as these policies are less likely to bring savings despite their public appeal.
This brief summarizes 2019 state legislative activity on surprise medical bills.
In this June 12, 2019 testimony before the U.S. House of Representatives Energy and Commerce Subcommittee on Health, Claire McAndrew, Director of Campaigns and Partnerships at Families USA, breaks down the problem with surprise medical bills and potential solutions under consideration by the committee.
High and rising prescription drug prices force consumers to skip doses or even avoid filling their prescriptions for life-saving medications altogether. Now is the perfect time for Congress to finally begin to take action by passing the bipartisan CREATES Act.